Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 50

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 50
---
on, D.V.M.  |     | 65%                   |     | $            | 470,243 |     |    |
| Amar Murugan            |     | 45%                   |     | $            | 231,750 |     |    |

(1) Dr. Nguyen’s initial 2024 base salary of $550,000 with a 45% target bonus was increased to $650,000 with a 60% target bonus in September 2024. Per his employment agreement for the 2024 calendar year, Dr. Nguyen’s bonus will be prorated based on his Start Date and, as such, Dr. Nguyen will be eligible for a prorated bonus equal to 45% of his prior base salary of $550,000 from January 1, 2024 through the Start Date and 60% of his based salary of $650,000 from the Start Date through December 31, 2024. (2) Mr. Hyllengren’s initial 2024 base salary was increased to $520,000 in October 2024. 2024 Corporate Goal Development, Weighting and Performance Evaluation In the first quarter of 2024, the Board reviewed and approved the corporate goals and objectives for 2024, as summarized in the table below. In selecting these goals, the Human Capital Committee wanted to incentivize fiscal discipline and the continued advancement of our development programs: tab-cel; and CAR-T. At the time the 2024 corporate goals were set, the Board and management believed that such goals were challenging, and that achieving them would require not only continued strong progress on research and clinical development, manufacturing and operational capabilities, and prudent fiscal and legal management, but also a high level of effort and execution on the part of our named executive officers.

<div align='center'>32</div>

The Board also applied a performance weighting to such goals relative to our overall performance to reflect the prioritization of key business objectives. The relative weighting between our 2024 corporate objectives relating to advancing key assets in our pipeline and is summarized below.

| 2024 Objectives | 2024 Goals Summary                                                                          | Results                                                                                                         | Weight |
| Tab-cel         | •File BLA in Q2 2024                                                                        
 •Receive FDA acceptance of BLA filing in Q3 2024                                            
 •Successfully Complete RTQs and PAI to enable BLA approval in HCT and SOT in Q1 2025        
 •Ob